Vor Biopharma (NASDAQ:VOR) Trading Up 8.3% – What’s Next?

Vor Biopharma Inc. (NASDAQ:VOR)’s share price shot up 8.3% on Wednesday . The company traded as high as $15.32 and last traded at $15.2650. 392,838 shares were traded during trading, a decline of 60% from the average session volume of 986,901 shares. The stock had previously closed at $14.10.

Analyst Ratings Changes

VOR has been the subject of a number of recent research reports. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wedbush lifted their price objective on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research note on Monday, May 18th. Finally, Wells Fargo & Company assumed coverage on shares of Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $42.25.

Vor Biopharma Stock Up 10.2%

The stock has a 50 day simple moving average of $15.07 and a two-hundred day simple moving average of $13.68.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Monday, March 30th. The company reported $307.61 EPS for the quarter. Equities research analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Insider Transactions at Vor Biopharma

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 589,257 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63. Following the transaction, the director directly owned 4,555,741 shares in the company, valued at $75,579,743.19. This represents a 11.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 3,002,903 shares of company stock valued at $49,412,176 over the last three months. Corporate insiders own 0.45% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. acquired a new stake in Vor Biopharma during the 4th quarter worth $36,000. Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma in the 2nd quarter valued at about $66,000. Chung Wu Investment Group LLC purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at about $134,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).